Neuraminidase is the enzyme the virus cannot live without. Once hemagglutinin has let a virion slip into a cell and the pathogen has copied itself, it is neuraminidase that clips the sialic acid receptors holding newborn particles tethered to the cell surface, freeing them to infect again. Antiviral drugs such as oseltamivir exploit precisely this dependence, which is one reason vaccinologists have argued for decades that antibodies against neuraminidase — antibodies that do not usually block infection outright but throttle viral replication — should translate into milder illness, shorter disease duration, reduced viral shedding and less transmission. Human challenge studies and large observational cohorts have indeed linked higher neuraminidase-inhibition titers with meaningful protection, particularly against severe disease. Neuraminidase also carries a structural dividend: its stalk domain, beneath the catalytic head, is considerably more conserved than the relentlessly drifting head of hemagglutinin, making it an attractive anchor for vaccines that must survive antigenic drift. The N2 subtype carries special historical weight, having entered humans during the 1957 “Asian flu” H2N2 pandemic and circulated, via the 1968 H3N2 reassortment, ever since.

Why, then, has neuraminidase languished? Part of the answer is manufacturing and measurement. Standard seasonal vaccines are quantified by their hemagglutinin content, a convention that leaves the amount and integrity of neuraminidase in each dose poorly controlled, and purified NA is a fragile, tetrameric enzyme that has historically been difficult to produce and stabilize at scale. Dedicated neuraminidase vaccines have therefore often delivered weaker immune responses than the field would like, and a consensus has grown that if NA is to carry more of the protective burden, it will need help from potent, well-characterized adjuvants. That is the gap the new study set out to address, and it chose its tools with an eye toward translational realism: rather than inventing novel immunostimulants, the team leaned on molecules with existing regulatory track records, asking whether familiar chemistry could be coaxed into unfamiliar performance.

The study’s central players are anything but exotic. Alum, the aluminum-salt colloid that has anchored licensed vaccines since the 1930s, is the workhorse of the adjuvant world: it binds antigen into particles that phagocytes readily engulf, prolongs antigen persistence at the injection site and reliably drives strong antibody responses — though it skews immune signaling toward Th2 pathways and is notoriously feeble at rousing the cellular arm of antiviral defense. CpG 1018, by contrast, is a synthetic, nuclease-resistant strand of DNA engineered to imitate bacterial genomes. Its unmethylated CpG motifs are seized by Toll-like receptor 9, an innate immune sensor buried in the endosomes of plasmacytoid dendritic cells and B cells, igniting the MyD88 signaling cascade, unleashing type I interferons and inflammatory cytokines and pushing the overall response toward a Th1, antiviral character. CpG 1018 has already proven itself in the licensed hepatitis B vaccine Heplisav-B and, in combination with alum, in Valneva’s inactivated whole-virus COVID-19 vaccine. What the research team now reports is that when both adjuvants are mounted around an N2 neuraminidase antigen, the immune outcome exceeds the sum of its parts.

Modern adjuvant development has increasingly embraced exactly this kind of rational pairing of an innate immune agonist with a delivery vehicle, as in the licensed system AS04, which couples the TLR4 agonist MPL to aluminum salt. The logic is mechanistic complementarity. A naive B cell requires not only antigen recognition but costimulatory instruction, delivered largely by activated dendritic cells; alum excels at shaping how antigen is presented and retained, while CpG 1018 excels at converting antigen-presenting cells into potent, interferon-secreting teachers and at directly co-stimulating B cells through TLR9. Together, the two can simultaneously increase the quantity of antigen available, the quality of its presentation and the intensity of the danger signal — a combination that, in principle, should deepen germinal-center reactions, expand populations of T follicular helper cells and sharpen antibody affinity maturation. What remained uncertain was whether such a partnership, delivered by conventional intramuscular injection, could reach beyond the bloodstream into the mucosal immune compartment that injected vaccines so rarely engage.

That uncertainty is what makes the findings striking. According to the paper, when the N2 neuraminidase vaccine was formulated with CpG 1018 and alum together, the responses it generated outperformed what either adjuvant achieved alone — the hallmark of true synergy rather than simple addition. The combined formulation drove markedly stronger serum antibody responses against the neuraminidase antigen, and, crucially, those antibodies were functional, showing enhanced activity in neuraminidase-inhibition assays — the laboratory readouts, classically performed as enzyme-linked lectin assays, that measure how effectively antibodies jam the enzyme’s catalytic head and that have repeatedly correlated with clinical protection in human studies. The systemic arm of immunity — the circulating IgG that travels through blood and tissue fluid and intercepts virus in the earliest hours of infection — was thus fortified on both quantitative and qualitative fronts. For a field in which neuraminidase-based vaccines have often struggled to produce antibody levels competitive with hemagglutinin-focused formulations, that result alone carries real weight.

The more consequential surprise lies in the mucosal compartment. Conventional injected vaccines are largely blind to the mucosa: they generate abundant serum antibodies but little of the secretory immunoglobulin A that bathes the lining of the nose, throat and bronchial tree, even though the respiratory tract is precisely where influenza makes first contact. Secretory IgA is a dimeric, highly specialized antibody ferried across the epithelial barrier by the polymeric immunoglobulin receptor, where it sits directly in the path of incoming virions, capable of neutralizing them before a single cell is infected. Yet the study reports that the CpG 1018–alum combination achieved what alum alone typically cannot: a substantive boost to mucosal as well as systemic defenses against the N2 antigen. The finding fits accumulating evidence that innate immune signals can instruct circulating B cells to acquire mucosal-homing properties, prompting them to seed respiratory tissues rather than remain sequestered in the systemic compartment. In effect, the adjuvant pairing appears to re-educate a needle-delivered vaccine so that its benefits arrive at the very doorway where infection begins.

Why should two chemically dissimilar molecules cooperate so effectively? The study’s results point to a division of labor that covers the principal bottlenecks of antigen-specific immunity. Alum constrains and presents the antigen, creating the particulate, phagocyte-friendly substrate from which antibody responses are built. CpG 1018 detonates the innate alarm: through TLR9 it drives interferon and co-stimulatory signals that transform antigen-presenting cells into far more persuasive instructors of naive lymphocytes. Where either input alone leaves gaps — alum’s weak Th1 tone, CpG’s limited capacity to retain and present antigen — the other fills them, producing the synergistic outcome the authors describe. Synergy in the immunological sense is a demanding standard: the combined response must exceed what would be predicted by simply adding each adjuvant’s individual contribution, which requires the components to engage complementary, mutually reinforcing pathways rather than duplicating one another. There is also a sober practical dividend. Neuraminidase is historically a difficult antigen to manufacture at high yield, and NA-based vaccines often require substantial antigen doses to elicit competitive titers. An adjuvant pairing that extracts more immunity per microgram of protein translates directly into dose-sparing capacity — an asset of enormous consequence in a pandemic, when manufacturing capacity and antigen supply become the binding constraints on global vaccine availability.

The strategic implications reach well beyond a single subtype. H2N2 vanished from human circulation in 1968, meaning most people alive today have never encountered either its hemagglutinin or its neuraminidase — a population-scale immune naivety that places H2 viruses high on the lists of potential pandemic threats maintained by global health authorities. Vaccines built around N2 neuraminidase and supercharged by an adjuvant pairing already embedded in licensed products could form part of the preparedness arsenal for such an emergence. For seasonal influenza, meanwhile, the findings feed a long-running argument that vaccines should incorporate neuraminidase alongside hemagglutinin to broaden coverage, blunt transmission and preserve protection against severe disease even in years when the hemagglutinin component is mismatched to circulating strains. And because both adjuvants are inexpensive, chemically simple, thermally robust and thoroughly woven into regulatory experience worldwide, the approach does not depend on the cold-chain fragility or manufacturing complexity that constrains newer platforms. It is, in a sense, a retrofit: established immune-stimulating chemistry applied to a second antigen the field has long undervalued.

None of this guarantees a swift path to the clinic. As with any early-stage vaccine study, the findings will need to survive human evaluation, where the performance seen in experimental models does not always predict outcomes in diverse, previously exposed populations — not least because the biology of Toll-like receptor 9 itself differs between species. Key questions remain open: how durable the mucosal responses prove to be, how well the strategy generalizes to other neuraminidase subtypes, what the optimal balance of CpG 1018 to alum might be, and how tolerable the intensified innate stimulation will feel in practice, since stronger danger signals can bring stronger reactogenicity. Standardizing neuraminidase-inhibition titers as a regulatory correlate of protection remains a work in progress. Even so, the study lands at a moment of gathering momentum, as funders and manufacturers begin to take the “second antigen” of influenza seriously. It suggests that the tools needed to build better flu defenses may already be sitting on the shelf — waiting, much like neuraminidase itself, for their full value to be recognized.

The human immunodeficiency virus (HIV) continues to challenge the global health community with its complexity and adaptability, necessitating bold and creative approaches to prevention. Traditional vaccine designs and systemic antibody therapies have encountered substantial hurdles, ranging from insufficient mucosal immunity to rapid viral evolution. Recognizing that sexual transmission through mucosal membranes remains a predominant pathway for HIV spread, the research team engineered a strategy that leverages localized delivery of protective agents directly to the vaginal mucosa, where initial viral invasion occurs.

At the heart of this scientific breakthrough lies messenger RNA (mRNA) technology, which has gained widespread recognition for its role in the COVID-19 vaccine revolution. Unlike conventional vaccines, mRNA platforms instruct host cells to transiently produce specific proteins—in this case, broadly neutralizing antibodies (bNAbs)—capable of neutralizing diverse strains of the virus. By encoding these antibodies directly into mRNA sequences and delivering them intravaginally, the researchers have circumvented many of the limitations associated with systemic antibody administration, such as rapid clearance and insufficient mucosal presence.

What distinguishes this methodology is not merely the deployment of mRNA but its finely-tuned delivery within a specialized vaginal gel matrix. This formulation ensures that the mRNA molecules are protected from enzymatic degradation and can efficiently transfect the epithelial cells lining the vaginal tract. Once internalized, these cells act as biofactories, transiently synthesizing potent antibodies directly at the mucosal surface, establishing a formidable frontline defense against viral entry. This localized expression was confirmed through rigorous in vivo models employing SHIV—a simian-human immunodeficiency virus hybrid commonly used to mimic HIV infection in preclinical studies.

Remarkably, the spectrum of protection achieved by this intervention goes beyond singular viral strains. The engineered antibodies possess enhanced breadth, meaning they can neutralize multiple SHIV/HIV variants with high potency. This is a critical attribute since HIV’s rapid mutation rate often undermines narrow-spectrum interventions. By focusing on conserved viral epitopes, the mRNA-encoded antibodies retain efficacy against a wide range of circulating strains, mitigating the risk of viral escape and breakthrough infections.

The implications of this research extend into the realm of female-centric prevention strategies, a domain historically underserved. Intravaginal delivery not only caters to anatomical and behavioral realities of sexual transmission but also empowers women with discreet, on-demand protection. This contrasts with systemic treatments which may require medical supervision or adherence to complex dosing regimens. As a user-applied gel, this platform has the potential for self-administration, fostering autonomy and broader accessibility, especially in resource-limited settings where the burden of HIV is disproportionately high.

Beyond efficacy, safety and tolerability formed a paramount aspect of this investigation. The researchers meticulously evaluated mucosal tissue response post-application, confirming minimal inflammation or adverse reactions. The transient nature of mRNA expression coupled with the body’s natural clearance mechanisms contributed to an excellent safety profile, easing concerns about long-term tissue disruption or immune hypersensitivity. This balance between robust antiviral activity and mucosal integrity underscores the therapeutic potential of this approach.

Moreover, the use of mRNA technology offers unparalleled flexibility in rapidly adjusting antibody sequences in response to emerging viral variants. This adaptability is crucial given the ever-shifting landscape of viral epidemiology. The rapid manufacturability of mRNA-based therapeutics further facilitates scalability, reducing production timelines and costs compared to traditional monoclonal antibody manufacturing processes. This aspect enhances the feasibility of widespread implementation, particularly in high-incidence populations.

In terms of translational impact, this research lays foundational groundwork for future clinical development phases. The promising preclinical results invite human trials aimed at validating pharmacokinetics, immunogenicity, and real-world efficacy. The integration of this platform within comprehensive HIV prevention programs—including education, testing, and antiretroviral therapies—could markedly shift the paradigm toward more effective containment of the epidemic.

Furthermore, the broader applicability of localized mRNA antibody delivery holds exciting prospects beyond HIV. Similar strategies might be harnessed to combat other sexually transmitted infections or mucosal pathogens by customizing the encoded antibodies. This modularity expands the horizon for mucosal immunotherapy and personalized medicine, illustrating a versatile platform emerging from foundational molecular biology insights.

Interdisciplinary collaboration has been instrumental in achieving this milestone. The fusion of molecular immunology, virology, pharmaceutical formulation, and bioengineering contributed to elucidating challenges and refining solutions at every stage. This integrative approach demonstrates how converging scientific fields can catalyze innovations with profound global health implications, redefining the boundaries of what is achievable in therapeutic design.

The study also emphasizes the importance of mucosal immunology as a frontier in infectious disease research. While systemic immunity has dominated the discourse for decades, understanding and targeting mucosal defense mechanisms reveal critical vulnerabilities in pathogen transmission chains. The local production of antibodies via mRNA transfection introduces a paradigm shift by empowering mucosal tissues to mount immediate and strategic responses to invading pathogens rather than relying solely on circulating antibodies.

Given the escalating urgency to curb HIV transmission and the limitations of existing preventive measures, such as condom use and pre-exposure prophylaxis, novel tools are indispensable. This research exemplifies how cutting-edge biotechnology can be harnessed to meet this challenge. By enhancing both the breadth and potency of protection directly at the initial sites of infection, mRNA-encoded antibodies delivered vaginally could revolutionize the public health landscape.

Ultimately, the promising findings resonate beyond the scientific community, igniting hope for millions vulnerable to HIV globally. As the world continues to grapple with emerging and endemic infectious diseases, innovations like this underscore the pivotal role of transformative scientific research in safeguarding humanity. The ongoing quest to translate these findings into accessible, effective interventions embodies the enduring human spirit to overcome our most formidable biological adversaries.

Subject of Research: Intravaginal delivery of mRNA-encoded antibodies for enhanced SHIV/HIV protection.

Article Title: Intravaginal delivery of mRNA-encoded antibodies with enhanced breadth and potency for SHIV/HIV protection.

Article References:
Joo, J.Y., Xiao, P., John, S.P. et al. Intravaginal delivery of mRNA-encoded antibodies with enhanced breadth and potency for SHIV/HIV protection. Nat Commun 16, 10463 (2025). https://doi.org/10.1038/s41467-025-65456-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65456-x

In a groundbreaking study, the laboratory of Professor Jan Terje Andersen has unveiled a novel vaccine technology platform that ingeniously fuses a subunit antigen to albumin. Albumin, a protein abundant in human serum, was selected due to its natural capability to be actively transported across mucosal barriers via the neonatal Fc receptor (FcRn), located on mucosal epithelial cells. This innovative approach aims to create vaccines that not only elicit a systemic immune response but also stimulate a robust mucosal immune response directly where respiratory pathogens enter the body.

The implications of this research are profound, as the potential for an effective means of vaccination against respiratory viral infections could reduce the frequency and severity of outbreaks. In preclinical studies conducted on various mouse strains, researchers demonstrated that the albumin-antigen fusion vaccines, delivered intranasally, prompted significant systemic and mucosal antibody responses. Notably, the mice exhibited considerable protection against viral challenges, such as those posed by SARS-CoV-2 and influenza A, underscoring the promise of this new vaccine platform.

One of the distinguishing features of this study is the strategic incorporation of adjuvants, which can enhance the immune response elicited by vaccines. In the novel albumin-based vaccine approach, these adjuvants were site-specifically conjugated to the albumin carrier, thereby allowing for an optimized immune response at the mucosal sites. This targeted approach is essential because the most effective vaccines are those that can induce high levels of immunoglobulin A (IgA) antibodies in the mucosal tissues, which play a critical role in neutralizing pathogens at the site of invasion.

Intriguingly, when comparing the new albumin-based vaccine strategy to established vaccine platforms, such as an intramuscularly administered mRNA vaccine or an intranasally delivered antigen fused to a protein carrier of similar size to albumin, only the albumin-based formulation led to robust mucosal IgA antibody responses. This finding highlights the unique advantages of using albumin as a carrier in vaccine design, making it a compelling candidate for future vaccine development targeting respiratory pathogens.

Professor Jan Terje Andersen, the senior author of the study, emphasized the critical need for improved vaccines against respiratory pathogens that are responsible for high mortality rates. His enthusiastic endorsement of the new vaccine technology reflects the potential it holds not only for immediate applications but also for future vaccine design. The albumin-based platform is adaptable, allowing for the antigen to be any identified protein subunit derived from infectious agents.

The engineering of a human albumin variant with an enhanced ability to engage FcRn paves the way for more effective antigen transport across mucosal barriers. This means that, following transport, the immune system can be primed to recognize and respond to the vaccine subunit effectively. The in-depth exploration of FcRn interactions and binding nuances across species has been vital to ensure that this vaccine technology is translatable and relevant across different biological contexts.

As the global community witnesses an increased frequency of respiratory viruses, the relevance of this research cannot be overstated. With the ongoing threat of pandemics, innovative vaccine technologies that respond to emerging infectious diseases are of utmost importance. The careful consideration of cross-species differences in immune responses further enhances the translational potential of this research, making it a promising contender in the race to develop effective vaccines for current and future viral outbreaks.

Moreover, the funding and support for this study, provided by organizations such as the Research Council of Norway, the South-Eastern Norway Regional Health Authority, the Coalition for Epidemic Preparedness and Innovation (CEPI), and Independent Research Fund Denmark, underscore the collaborative effort required to address these pressing public health challenges.

As scientists continue to refine and expand upon this vaccine platform, it is essential to engage in further research that explores its efficacy against a wider array of respiratory pathogens. The potential to develop a vaccine that can efficiently elicit a robust immune response at mucosal surfaces could revolutionize the way we approach the prevention of respiratory illnesses. Continued investigation into the nuances of immune responses elicited by the albumin-based vaccines will provide deeper insights and further establish its place in future vaccine design.

In conclusion, the findings from Professor Andersen and his team mark a significant advancement in vaccine research and open new avenues for the development of effective vaccines against respiratory pathogens. Their innovative albumin-based vaccine technology platform represents a remarkable stride towards achieving protection at the very locations where infections initiate. As the scientific community moves forward, this work lays a strong foundation for future endeavors aimed at enhancing the efficacy of vaccines in combating the next wave of viral threats facing global health.

Subject of Research: Novel vaccine technology for respiratory pathogens
Article Title: An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models
News Publication Date: 1-May-2025
Web References: https://doi.org/10.1038/s41467-025-59353-6
References: Available upon request
Image Credits: N/A

Keywords

Vaccine, mucosal immunity, respiratory pathogens, albumin, FcRn, COVID-19, influenza, antibody responses, vaccine technology, immunology, translational research.